马来酸噻吗洛尔滴眼液治疗婴幼儿血管瘤125例临床观察

The Clinical Observation of Timolol Maleate Ophthalmic Solution for 125 Casesof Infantile Hemangioma

目的评价马来酸噻吗洛尔滴眼液局部外用治疗婴幼儿血管瘤的临床疗效和安全性。方法对入选的125例血管瘤患儿予马来酸噻吗洛尔滴眼液局部外用,每日早、晚各使用1次,间隔时间12 h,共治疗6个月,最后用Achauer疗效评定法判定临床疗效。结果Ⅰ级9例(7.20%),Ⅱ级28例(22.40%),Ⅲ级65例(52.00%),Ⅳ级23例(18.40%),浅表型血管瘤的疗效优于深部型及混合型血管瘤的疗效(P<0.05)。超声多普勒血流仪检查结果显示浅表型血管瘤经治疗后血流峰值减少,并阻力系数增加(P<0.05)。125例患儿均未见明显不良反应。结论马来酸噻吗洛尔滴眼液外用治疗浅表婴幼儿血管瘤疗效明显,且无明显不良反应。

Objective To evaluate the clinical efficacy and safety of topical timolol maleate ophthalmic solution on infantile hemangioma. Methods A total of 125 cases of infantile hemangioma had been treated with topical timolol maleate ophthalmic solution twice a day, once in the morning and once at night, with a interval of 12 hours, for 6 months and then the clinical efficacy was determined by the Achauer curative effect evaluation method. Results All patients were derided into 4 groups, respectively as 9 cases （7.20%） of grade I , 28 cases （22. 40% ） of grade 11 ： 65 cases （52.00%） of grade Ⅲ, and 23 cases （ 18.40% ） of grade IV. The curative effect of superfical infantile hemangiomas is significantly more than the deep and mixed hemangioma （ P 〈 0. 05 ）. The result of ultrasonic doppler blood flowmete indicated a reduction of peak flow and an increase of drag coefficient in superficial hemangioma treated group（P 〈0. 05）. All patients showed no significant adverse reactions. Conclusion The timolol maleate ophthalmic solution has a significant curative effect to superficial infantile hemangioma without significant adverse reactions.